Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Surgery Risk Assessment Clear all
Recruiting Not applicable Interventional

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

NCT04251052
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
Procedure · Other
Lead sponsor
NRG Oncology
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
1,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2047
U.S. locations
564
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Terminated Phase 2 Interventional Results available

A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.

NCT05524051
View directory record Official record
Conditions
Acute Kidney Injury Following Cardiac Surgery
Interventions
TIN816, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 100 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

NCT01667536
View directory record Official record
Conditions
Prostate Cancer
Interventions
Drug: 99mTc-MIP-1404
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Duarte, California • Rochester, Minnesota • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Supporting Decision Making for Musculoskeletal Preference-Sensitive Care

NCT01345123
View directory record Official record
Conditions
Knee Pain Chronic, Arthritis (Hip), Arthritis (Knee), Back Pain
Interventions
Provision of condition specific shared decision making (SDM) aids only, Telephonic outreach and support by Health Coach
Behavioral
Lead sponsor
Health Dialog
Industry
Eligibility
18 Years and older
Enrollment
9,925 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 23, 2026, 11:35 AM EDT
Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
8
States / cities
Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Terminated Not applicable Interventional

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

NCT00017134
View directory record Official record
Conditions
Ovarian Cancer
Interventions
fenretinide, conventional surgery
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
35
States / cities
Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 23, 2026, 11:35 AM EDT
Active, not recruiting Not applicable Interventional

The JenaValve ALIGN-AR Pivotal Trial

NCT04415047
View directory record Official record
Conditions
Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
Interventions
JenaValve Trilogy Heart Valve System
Device
Lead sponsor
JenaValve Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 23, 2026, 11:35 AM EDT
Not yet recruiting Phase 2 Interventional

Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

NCT07118449
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
XC001, A195/placebo
Drug
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain

NCT00819286
View directory record Official record
Conditions
Sternal Wound Infection, Sternal Non-union, Pain, Mediastinitis
Interventions
SternaLock Rigid Fixation Plates, wire (control)
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Phoenix, Arizona • Sacramento, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 23, 2026, 11:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stanford PIPRA Validation Study in an Elderly Orthopedic Population

NCT06567574
View directory record Official record
Conditions
Delirium, Postoperative Delirium, Cognitive Impairment
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
65 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 2 Interventional

A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting

NCT00108095
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Interventions
intravenous ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Arcadia, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 23, 2026, 11:35 AM EDT
Active, not recruiting Phase 2 Interventional

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

NCT02949284
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
Drug · Biological · Other + 1 more
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional Results available

The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions

NCT01450631
View directory record Official record
Conditions
Post-operative Complications, Surgical Site Infection, Surgical Wound Infection
Interventions
Prevena™ Incision Management System (PIMS), Standard-of-care Dressing
Device
Lead sponsor
KCI USA, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 2 Interventional

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

NCT00157716
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
Interventions
(MC-1) Pyridoxal-5'-phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2006 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional Results available

CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

NCT00643617
View directory record Official record
Conditions
Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms, Cancer of the Prostate
Interventions
CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk
Radiation
Lead sponsor
Accuray Incorporated
Industry
Eligibility
18 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
18
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 23, 2026, 11:35 AM EDT
Withdrawn Phase 2 Interventional

Transdermal Continuous Oxygen Therapy for Infection Prophylaxis in High- Risk Patients Undergoing Colon Surgery

NCT02617706
View directory record Official record
Conditions
Anorectal Surgeries
Interventions
Epiflo
Device
Lead sponsor
Neogenix, LLC dba Ogenix
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 23, 2026, 11:35 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Longitudinal Study Looking at the Prevalence, Risk Factors & Consequences of Persistent Post-surgical Pain in Children

NCT06354699
View directory record Official record
Conditions
Chronic Pain
Interventions
Not listed
Lead sponsor
Telethon Kids Institute
Other
Eligibility
Up to 16 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate Non-significant Risk Operation Magnetic Resonance Imaging for MRI Guided Ablation

NCT04880226
View directory record Official record
Conditions
Healthy
Interventions
Magnetic Resonance Imaging (MRI)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Results available

Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

NCT00087022
View directory record Official record
Conditions
Kidney Cancer
Interventions
girentuximab, placebo
Biological · Other
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years to 120 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
39
States / cities
Anchorage, Alaska • Los Angeles, California • San Francisco, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV

NCT00952133
View directory record Official record
Conditions
PONV
Interventions
Palonosetron only, Palonosetron with Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 23, 2026, 11:35 AM EDT
Completed No phase listed Observational

Comparing Blood Loss, RBC Transfusions and Inflammatory Marker Changes Among Methods of CPB

NCT01083914
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 23, 2026, 11:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

REACH VET Implementation Program Evaluation

NCT03280225
View directory record Official record
Conditions
Suicide
Interventions
External facilitation
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
North Little Rock, Arkansas • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 23, 2026, 11:35 AM EDT
Not listed No phase listed Observational

Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

NCT04615091
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Surgery--Complications
Interventions
Not listed
Lead sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 23, 2026, 11:35 AM EDT
Terminated Phase 2 Interventional

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

NCT00271167
View directory record Official record
Conditions
Heart Diseases, Postoperative Complications
Interventions
INO-1001
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 23, 2026, 11:35 AM EDT